Catalyst Event
Merck and Co Inc (MRK) · Other
From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)
6/8/2026, 12:00:00 AM
Merck and Gilead announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study for Keytruda in combination with Trodelvy for NSCLC after failing to meet its primary endpoint; estimated 5% price impact due to clinical failure, expected.
Korean Translation
머크와 길리어드는 비소세포폐암(NSCLC) 대상 키트루다와 트로델비 병용 3상 임상이 1차 평가변수 미충족으로 중단되었음을 발표함. 임상 실패에 따른 약 5% 주가 영향 예상됨.
Related Recent Events
Synopsys Inc (SNPS) · Other
An investor day to discuss long-term financial targets and strategy is scheduled.
9/30/2026, 12:00:00 AM
Broadcom Inc (AVGO) · Earnings Release
Broadcom's Q3 2026 earnings release on September 3, 2026. This event is expected to have a medium impact as it will provide critical updates on AI revenue growth, scheduled
9/3/2026, 12:00:00 AM
NetApp Inc (NTAP) · Earnings Release
Next quarterly earnings for Q1 fiscal year 2027 are scheduled.
8/26/2026, 12:00:00 AM
HEICO Corp (HEI) · Earnings Release
Next quarterly earnings for Q3 2026 are scheduled to be reported on 2026-08-24, with analysts forecasting an EPS of $1.46; low importance is estimated as market impact is typically limited for scheduled announcements, scheduled.
8/24/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Walmart is scheduled to release its Q2 FY2027 earnings results on 2026-08-20, scheduled. Medium importance is estimated as earnings releases typically trigger significant market volatility.
8/20/2026, 12:00:00 AM
Microsoft Corp (MSFT) · Other
Microsoft declared a quarterly dividend of $0.91 per share with an ex-dividend date of August 20, 2026, scheduled.
8/20/2026, 12:00:00 AM